Renerve Limited · ASX:RNV
Renerve — Shareholder Meeting (November 2025)
21 slides from Renerve's shareholder meeting presentation, Nov 27, 2025
Slide 1: Transforming Nerve Repair Through Science Update
ASX:RNV Sales & Transforming Nerve Repair Marketing Through Science Update ReNerve ReNerve BoardGeneral Annual meeting | July 2025 Meeting presentation | November 2025 1
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer Disclaimer: No representation or warranty, express or implied, is made by the Company Nature of Document: This presentation has been prepared and issued by ReNerve Ltd that the material contained in this presentation will be achieved or proved correct. Except (Company)
Slide 3: Executive Summary
Executive Summary Development of Novel Nerve Repair & Regeneration Products ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial position and demand. Expanding Product Portfolio 3 pr
Slide 4: Activities for the past 12 months
Completed an ASX IPO Multiple regional partners Activities for the ● Middle East, Mexico, India, Hong Kong past 12 months Partnership with Berkeley Biologics ● Brings Empliq brand of products ● Adds 4 product lines to the ReNerve sales portfolio ● Helps accelerate company sales Expanding our ● Compl
Slide 5: Company Portfolio
Company Portfolio Product Product Commercial On Market R&D Development Development Nerve Cuff Nerve Tube Nerve Protector Nerve Guide Matrix Nerve Cap Dermal Tissue AmnioLite AmnioDuo Placental
Slide 6: Target Market
2031 Target USD$6.0Bn USD$6.19Bn Market The Global Nerve Repair Biomaterials Market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD$6.19Bn. Our Target Markets Global Nerve Repair Biomaterial Market 2025 Dermal and Amniotic Tissue USD$2.0Bn Surgical Appl
Slide 7: ReNerve's Nerve Opportunity
ReNerve’s Nerve Opportunity Nerve Cuff Nerve Conduit Nerve Guide Matrix Bionic Nerve • Used on damaged or transected • Improved Nerve Cuff developed from • An ‘off-the-shelf’, ready to use nerve • An ‘off-the-shelf’, continuous nerve Product nerves with no gaps or gap closure scCO2 tissue, offering
Slide 8: Global Nerve Repair Biomaterial Market
Global Global Nerve Repair Biomaterial Market Global Market by Segment $8.0Bn Nerve Repair 16% $6.0Bn 32% Biomaterial $4.0Bn USD $Bn Market $2.0Bn 52% - Nerve Wrap 2024 2025 2026 2027 2028 2029 2030 2031 Nerve Conduit North America Europe Nerve Grafts USD$1.69Bn ~900k Nerve Compression The Global Ne
Slide 9: Distribution Network
Distribution Network US Market Expanded Distribution Channels Robust portfolio • Expanded to 21 distributors across the US • Full logistics, warehousing and invoicing in place • Distributors can sell the entire ReNerve product range • Will add additional to the network as products come to market Foc
Slide 10: Ex-US Sales & Marketing
Ex-US Sales & Marketing Sales Highlights ReNerve Distribution Final stages of approval process in India India Asia MIDDLE EAST Seeking multiple approval applications across Asia Significant potential due to population On market in Hong Kong and Entered into exclusive partnership and open market. Hav
Slide 11: Nerve Cuff
ReNerve NervAlign Nerve Cuff ReNerve NervAlign Z on < & & = Nerve Cuff
Slide 12: Key Features
Key Features ReNerve’s “Align” 1 Product • Protects nerves during recovery post peripheral nerve Clinical Study repair • Great handling characteristics and absorbed within 6 Patient Results months 2 Definitive clinical study on using NervAlign Nerve Patient Benefit Cuff for nerve repair 120 patients
Slide 13: The "Align" Study
The “Align” Study Clinical Study on the NervAlign® Nerve Cuff Undertaking a definitive study in nerve repair following surgical neurolysis to show the benefit of protecting the nerve post nerve Comparison of Patient Pre & Post repair surgery. Surgery Pain Score 7.1 7.1 Study Design: Two patient coho
Slide 14: Product Range
ReNerve << Empliq Product Range
Slide 15: Empliq Product Portfolio
Empliq Product Portfolio Empliq AmnioLite Empliq AmnioDuo Empliq Placental Empliq Dermal Description Single-layer amniotic membrane Double-layer amniotic membrane Placental allograft including amniotic Deep-layer dermal matrix allograft allograft membrane and chorion Clinical Value Natural barrier t
Slide 16: Product Development Pipeline
Product Development Pipeline 16
Slide 17: Product Development Pipeline
Product Development Pipeline Nerve Nerve Conduit and protector ranges conduit range ● Includes the Nerve cap ● Entering commercial validation batches ● 3 types of conduits to come to market In the commercial development phase Nerve FDA approval pathway confirmed guide matrix Next step GMP, commercia
Slide 18: Value drivers for the next 12 months
Empliq products ranges Continue to expand into now in the US market Ex-US markets Value drivers for the next 12 months ● ● 4th product coming to market Complements the nerve cuff ● ● Establishing partners Ex-USA Pending approval in several ● Faster sales growth through countries in 2026 multiple pro
Slide 19: Company Milestones
Company Milestones 2025 Next 6 months Near Term Partnership Signed for Mexico Market NervAlign® Nerve Conduit into Market Nerve Guide Matrix GMP production R&D Tax Incentive Refund Received Growing the Empliq brand ReNerve ‘Align’ Study data Thailand Approval & First Hong Kong Sale Initial Clinical
Slide 20: Investment Highlights
Investment Highlights In Market Products Immediate Market Need Growing Market Nerve Cuff transitioned from R&D to Products promote nerve injury recovery and Nerve repair biomaterials and related markets commercial sales with 3 product lines in wound repair leading to faster patient are forecast to g
Slide 21: Contact
ASX:RNV Contact ReNerve Limited +61 (03) 9482 3940 info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia